Navigation Links
NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease
Date:11/20/2012

NESS ZIONA, Israel, November 20, 2012 /PRNewswire/ --

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

In pre-clinical studies of ND0612, plasma concentrations of levodopa reached straight-line steady state levels. The current Phase I double-blind, dose-escalation trial in young, healthy volunteers will assess ND0612 for safety and tolerability as well as for levodopa and carbidopa steady state plasma levels.

"This first trial of ND0612 in man is a significant step in the development of a new levodopa treatment standard for Parkinson's disease," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "For many years, oral levodopa has been the leading Parkinson's disease drug therapy. However, due to low and erratic oral levodopa bioavailability, advanced Parkinson's patients suffer from debilitating motor complications even under the best current standard of care. Should ND0612 achieve constant levodopa base blood levels, than low, harmful levodopa trough levels would be prevented, the efficacy of current levodopa therapy could be significantly raised and a new standard of care in our ability to treat and reduce motor complications in Parkinson's disease patients may be established."

About Parkinson's Disease

Parkinson's disease affects approximately 6M patients in the world. It is caused by decreasing dopamine signaling in the brain as dopaminergic brain cells die off. Levodopa is the "Gold Standard" therapy for Parkinson's disease and virtually all patients receive it. When administered thro
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... , Aug. 21, 2014  The board of ... a leading provider of clinical trial imaging solutions, today ... named chief financial officer, effective immediately.  Mr. Groff has ... August 2013.  He joined VirtualScopics in January 2006 as ... February 2013. "When the board of VirtualScopics ...
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) and Chelsea Therapeutics ... micro-dosing trial of an,I-3D compound. , The ... the pharmacokinetic,characteristics of the compound in humans. ... The study demonstrated that the selected I-3D ...
... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... data from the Ranolazine Open Label,Experience (ROLE) program, ... to be safe and well,tolerated in patients with ... 3 clinical trials, and enrolled in the ROLE,program. ...
Cached Medicine Technology:Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
(Date:8/21/2014)... The "North American Interventional ... by Angioplasty Balloon (Plain/Old, Cutting), Stent ... Filter (Retrievable), Endovascular Stent Graft - ... the major market drivers, restraints, and ... , Browse 108 market data tables ...
(Date:8/21/2014)... Rebecca Tabbert, owner of Calimesa Fit Body ... enjoyed watching as more people turn away from the ... camp environment. It’s not only good for her business; ... ‘treadmill-dumbbells-elliptical’ routine just doesn’t work,” she says. “Numerous research ... and lifting those cute little dumbbells does very little ...
(Date:8/21/2014)... Bedros Keuilian’s Annual Fitness Business Summit is considered ... many people already earning seven-figure incomes. But his annual ... open to the owners of Keuilian’s own international fitness boot ... Body Boot Camp World Conference will also be attended by ... camp or are struggling with their own boot camp ...
(Date:8/21/2014)... Chicago, IL (PRWEB) August 21, 2014 ... EB-5 Business & Investment Exploratory Delegation to southern China ... unique opportunity to explore the rapid growing cities of ... each delegate will have the rare opportunity to meet ... their project(s) during a short weeklong time frame. ...
(Date:8/21/2014)... August 21, 2014 mynt welcomes industry ... promoters to join its growing company. Since its pre-launch ... in product sales and continues to gain momentum leading ... , Rob and Tiffanie came into network marketing by ... a number of network marketing companies. Tiffanie needed help ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Calimesa Fit Body Boot Camp Announces Its Release of a New Video about the Fitness Boot Camp Experience 2Health News:Calimesa Fit Body Boot Camp Announces Its Release of a New Video about the Fitness Boot Camp Experience 3Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Artisan Business Group announces 2014 EB-5 Investment Trade Mission to China 2Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
... (HealthDay News) -- A combination of animal and human research ... could ultimately help in the treatment of major depression, researchers ... a brain protein known as p11. The study authors cite ... of reward, pleasure and satisfaction with positive life experiences. ...
... its Construction Unit, is participating in and coordinating a ... aim is to develop pest control products with lower ... and less damaging for human health. The two years ... Swedish University of Agricultural Sciences (SLU) and five SME ...
... car increases global temperatures in the long run more ... to a new study. However, in the short run ... because airplanes strongly affect short-lived warming processes at high ... & Technology , a semi-weekly journal. In the ...
... , TUESDAY, Oct. 19 (HealthDay News) -- A small group ... stop taking the cancer drug Gleevec (imatinib) have remained cancer-free ... online Oct. 19 in The Lancet Oncology , is ... go beyond long-term cancer control and offer some patients a ...
... Atlanta, GA, 20 October, 2010 Elsevier / MC ... than 1,300 healthcare organizations, has partnered with the Association ... module for Mosby,s Nursing Skills: Perioperative Collection, the only ... to be consistent with the Standards and Recommended ...
... , WEDNESDAY, Oct. 20 (HealthDay News) -- People with the ... serious eye damage, says a small new study from Greece. ... located near the center of the retina at the back ... vision and the processing of light. In this study, ...
Cached Medicine News:Health News:Animal Study Explores Potential Gene Therapy for Depression 2Health News:Animal Study Explores Potential Gene Therapy for Depression 3Health News:Tecnalia develops environment-friendly and health-friendly pest control products 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 3Health News:Elsevier/MC Strategies and AORN launch perioperative nursing skills collection 2Health News:People With Anorexia May Risk Serious Eye Damage 2
... offers improved ergonomics for today's exacting ... grippy finger rest and the large ... efficiency. Finnpipette Digitals also feature soft-touch ... (pat. pend.) and super blow-out for ...
... AlphaPette Pipettor is the #1 Pipettor ... accuracy, comfort, and reliability. Continuously adjustable. ... readout sub-micrometer. Easy interchangeable ejector buttons ... hands. Adjustable rapid pipet tip ejector ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
Research Series 2100 Adjustable-volume Pipette, 10-100 l, single-channel with adjustable-volume setting...
Medicine Products: